Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
about
Interventions for pemphigus vulgaris and pemphigus foliaceusSeverity score indexes for blistering diseasesScoring systems in pemphigusManagement of Pemphigus VulgarisManagement of pemphigus vulgaris: challenges and solutionsNeonatal Autoimmune Blistering Disease: A Systematic Review.Jean-Claude Bystryn 1938-2010. An obituary.Shifting Focus in the Therapeutics of Immunobullous Disease.Rituximab: A Magic Bullet for PemphigusRelevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.Evaluation of cases of pemphigus vulgaris and pemphigus foliaceus from a reference service in Pará state, BrazilEfficacy and safety of rituximab treatment in Indian pemphigus patients.Reliability and convergent validity of two outcome instruments for pemphigus.The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus.Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.Management of pemphigusAnalysis of the reactivity of indirect immunofluorescence in patients with pemphigus foliaceus and pemphigus vulgaris using rat bladder epithelium as a substrate.Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.Rituximab therapy improves recalcitrant Pemphigus vulgaris.Pemphigus vulgaris in a pregnant woman and her neonateInhibitory human antichimeric antibodies to rituximab in a patient with pemphigusQuality of Life Assessment in Korean Patients with PemphigusRituximab in the treatment of pemphigus vulgaris.Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus.Rituximab for autoimmune blistering diseases: recent studies, new insights.Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF).Seeking approval: present and future therapies for pemphigus vulgarisReliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaireSetting the target for pemphigus vulgaris therapy.Approach to the patient with autoimmune mucocutaneous blistering diseases.Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.Constructing immunoprofiles to deconstruct disease complexity in pemphigus.Pemphigus autoimmunity: hypotheses and realities.Alopecia as a rare but distinct manifestation of pemphigus vulgaris.Urban legends: pemphigus vulgaris.Cytokine networks in Pemphigus vulgaris: An integrated viewpoint.
P2860
Q24241277-66195613-350C-4D1A-B6C6-8E7FADBB824CQ24604349-AD58D56B-0577-4A2E-BB27-9252A4F6CFD9Q24624530-B34980EF-1EB4-4852-8166-E453F0F78A30Q26747092-F90BFCD9-1681-4B67-BE61-DB054E954C46Q26778895-5FA22664-EF89-4136-8B1F-62A0B3C503BBQ30251572-6E3A4C0D-F2D3-4B36-94E4-78C7C1D5A25CQ30399726-74CBCC30-EE8A-4086-88C2-9752AF28577EQ33737974-8FA6DB09-0EE9-4432-B525-1AC636DCA653Q33741941-E2D11718-AF61-4B34-80E1-051C8B37C99CQ33971785-76B03614-FBCF-47CF-8F4F-436EF3EA4FEEQ34067962-56551EDD-D203-4197-AB88-931B20C77A24Q34104792-701F5316-486A-4D1F-87BA-E8224EF6CCE1Q34241174-C068FE33-7582-4358-8F17-57039822C7A0Q34441185-1110C538-8AB6-473C-A13E-A106999FE077Q34457946-3F5AC873-93F9-427C-B421-BE0D21CBF9F5Q34504542-F499A6D3-A0D4-46A7-B080-D3FE952EEA1FQ34964558-B55D59A0-7FAC-48DB-B86E-4B6D97ACAD89Q35173849-12738AD9-FC82-4764-AD70-DC248F14A5C6Q35580180-67ACEBFE-7BE1-44CD-9B27-89633BD89A7FQ35922554-61A1ECFF-8049-4BD0-9EAA-68416F321A54Q36008711-41DB1563-43A9-4B09-A4EF-31379A1CD354Q36069972-5C72ECF7-FC0F-4E73-BF67-B709B53E9AA8Q36140831-68CEE9DA-11A5-4BDF-A0FD-4646B12E467FQ36214204-96101B86-FB9D-4B80-9639-532DFA8F4397Q36434853-AD563A11-9CFD-456E-A3B6-715C8145B75AQ36446786-3ADB3601-BC33-4E93-90E5-69CB4776375FQ36607392-DC828D00-EFC9-4C1B-9AD5-7B47D8EB489AQ36751954-071CEED5-7641-4CD1-8E43-31670D30C266Q36857368-969B51BC-DBF8-4BA4-862A-61899AA22A3DQ36858786-04396025-AB65-4F64-A7A7-27AFB85911ECQ37157777-A4259AD1-9D48-497A-807B-08793FD8D152Q37622933-83547538-A923-4774-9963-5384B4D28F54Q37677416-7683B0AC-3634-4908-8933-855EA9FFE3DFQ37853595-AF7F8505-BCB6-41DE-B961-B014B18D6B72Q37933423-AF9DA760-22C8-4109-8156-C88E9E97905BQ37933433-5554F64B-1E45-44E0-A22A-A56CCAFA6982Q37937040-32E29280-F779-42D9-933C-87C3ED01A822Q37961795-7F676005-262E-4438-B93C-2A1038F4B6C2Q37984131-B10E2154-41DD-4478-827C-22752C730A1FQ38017731-3CE0C5A8-C2F5-4C7D-9AAC-F2E750C5F53E
P2860
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Consensus statement on definit ...... peutic response for pemphigus.
@ast
Consensus statement on definit ...... peutic response for pemphigus.
@en
type
label
Consensus statement on definit ...... peutic response for pemphigus.
@ast
Consensus statement on definit ...... peutic response for pemphigus.
@en
prefLabel
Consensus statement on definit ...... peutic response for pemphigus.
@ast
Consensus statement on definit ...... peutic response for pemphigus.
@en
P2093
P1476
Consensus statement on definit ...... peutic response for pemphigus.
@en
P2093
Aimee S Payne
Amit G Pandya
Animesh A Sinha
Daniel Mimouni
David Fivenson
David Rubenstein
David Sirois
Dedee F Murrell
Giuseppe Cianchini
P304
P356
10.1016/J.JAAD.2008.01.012
P407
P577
2008-03-14T00:00:00Z